---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-082897"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2026-07-13T12:30:43+00:00"
generated_at: "2026-07-13T12:35:14.982453+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocugen signs binding term sheet with Roots Pharmaceutical to license OCU400 in MENA; up to $255M milestones, 22% royalty

## Summary
- Upfront and near-term development milestones up to $4M; sales milestones up to $255M.
- Ocugen to receive 22% royalty on net sales of OCU400 in MENA region.
- Definitive license agreement expected within 90 days; Ocugen to manufacture supply.
- OCU400 is a modifier gene therapy for retinitis pigmentosa, a leading cause of inherited vision loss.

## SEC filing metadata
- accession: 0001104659-26-082897
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2026-07-13T12:30:43+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465926082897/0001104659-26-082897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465926082897/tm2620295d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-082897
- JSON: https://secwatch.observer/filing/0001104659-26-082897.json
- Plain text: https://secwatch.observer/filing/0001104659-26-082897.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.